<DOC>
	<DOCNO>NCT01777529</DOCNO>
	<brief_summary>Whether low immunogenicity mumps component obtain clinical study MMR Brazil , due multidose presentation . Investigations make factor could interfere immunogenicity mumps component , kit use immunoassay method , potency vaccine , explanation find . This study aim investigate hypothesis lower immunogenicity mumps component MMR Bio-Manguinhos vaccine , due multidose presentation . The Main objetctive evaluate immunogenicity MMR one dose child 12 23 month life , compare performance multidose vial ( 10 dos per vial vaccine produce Bio-Manguinhos/Fiocruz technology transfer GlaxoSmithKline Laboratory - GSK ) single dose vial ( 1 dose per vial vaccine produce GSK ) .</brief_summary>
	<brief_title>Comparative Study Immunogenicity MMR ( Measles , Mumps Rubella ) Single Dose Multidose Presentations</brief_title>
	<detailed_description>Study Design This clinical trial Phase IV , randomize , single-blind , two arm : - MMR ( TV ) combine measles , mumps rubella vaccine produce Bio-Manguinhos , apply healthy child 12 23 month . Multidose presentation , one batch . - MMR ( GSK-TV ) , produce GlaxoSmithKline , age . Monodose presentation , one batch . Locations study - CMS Heitor Beltrão - Tijuca - CMS Milton Fontess Magarão - Engenho de Dentro - CMS Waldyr Franco - Bangu</detailed_description>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children sex . Age 12 23 month 29 day . Child good health , without significant personal morbid history , genetic syndrome , epilepsy , diabetes , severe infection immune dysfunction . Concordance father mother , legal guardian , child 's participation study , sign Informed Consent Form ( ICF ) . Disposition father mother , legal guardian , provide name , address , telephone number information get touch ( ) necessary . Responsible able understand risk experiment , although minimal , . Responsible able understand sign inform consent form . If charge able sign ( illiterate ) ICF may sign impartial witness follow whole procedure . Availability return collect postvaccination The subject research may participate another clinical trial study . Not received vaccine Immunization Schedule last 30 day . Not receive another vaccine harvest 2 , 42 day vaccination MMR . Noninclusion criterion Children history measles , rubella mumps . Having previously receive MMR vaccination document book ( eg situation conduct national campaign block vaccination suspect case disease ) . Have receive injectable vaccine live attenuate ( eg . Yellow fever vaccine ) case , defer vaccination MMR 30 day last live attenuate vaccine administer . Having receive transfusion blood blood product , include immunoglobulin , less 1 year . Skin lesion sit venipuncture . Child subject abnormal bleeding injection . Use last 6 month immunosuppressive dos corticosteroid immunosuppressant . Fever day inclusion 3 day prior inclusion case may reschedule inclusion 14 day fever subsides . Use antibiotic day inclusion last 7 day prior date inclusion case , may reschedule inclusion 14 day last day antibiotic use . Any significant abnormality physical examination day enrollment . Hypersensitivity known systemic neomycin component vaccine . Guy history severe allergy , anaphylaxis egg protein</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Measles</keyword>
	<keyword>Mumps</keyword>
	<keyword>Rubella</keyword>
</DOC>